Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: lactose monohydrate; maleic acid; sodium stearylfumarate; croscarmellose sodium; hypromellose - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

strides pharma science pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: hypromellose; sodium stearylfumarate; maleic acid; croscarmellose sodium; lactose monohydrate - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - enalapril maleate, quantity: 5 mg - tablet - excipient ingredients: croscarmellose sodium; sodium stearylfumarate; lactose monohydrate; maleic acid; hypromellose - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - lercanidipine hydrochloride, quantity: 10 mg; enalapril maleate, quantity: 20 mg - tablet, film coated - excipient ingredients: lactose monohydrate; sodium bicarbonate; purified talc; quinoline yellow aluminium lake; sodium starch glycollate type a; iron oxide yellow; magnesium stearate; microcrystalline cellulose; hypromellose; titanium dioxide; povidone; macrogol 6000 - treatment of hypertension. treatment should not be initiated with these fixed dose combinations. (see dosage and administration).

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

remedyrepack inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate is indicated for the treatment of hypertension. enalapril maleate is effective alone or in combination with other antihypertensive agents, especially thiazide-type diuretics. the blood pressure lowering effects of enalapril maleate and thiazides are approximately additive. enalapril maleate is indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate improves symptoms, increases survival, and decreases the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate decreases the rate of development of overt heart failure and decreases the incidence of hospitalization for heart failure (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trial

Vereinigte Staaten - Englisch - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - enalapril maleate (unii: 9o25354epj) (enalaprilat anhydrous - unii:q508q118jm) - enalapril maleate tablets are indicated for the treatment of hypertension. enalapril maleate tablets are effective alone or in combination with other antihypertensive agents, especially thiazidetype diuretics. the blood pressure lowering effects of enalapril maleate tablets and thiazides are approximately additive. enalapril maleate tablets are indicated for the treatment of symptomatic congestive heart failure, usually in combination with diuretics and digitalis. in these patients enalapril maleate tablets improve symptoms, increase survival, and decrease the frequency of hospitalization (see clinical pharmacology, heart failure, mortality trials for details and limitations of survival trials). in clinically stable asymptomatic patients with left ventricular dysfunction (ejection fraction ≤35 percent), enalapril maleate tablets decrease the rate of development of overt heart failure and decrease the incidence of hospitalization for heart failure (see clinical pharmacology, hear

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 20 mg - tablet, uncoated - excipient ingredients: zinc stearate; hypromellose; maleic acid; iron oxide yellow; lactose monohydrate; maize starch; iron oxide red - hypertension. enalapril gh is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril gh is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - enalapril maleate, quantity: 10 mg - tablet, uncoated - excipient ingredients: maize starch; hypromellose; zinc stearate; maleic acid; lactose monohydrate; iron oxide red - hypertension. enalapril gh is indicated in the treatment of: all grades of essential hypertension; renovascular hypertension. congestive heart failure. enalapril gh is indicated in the treatment of all degrees of symptomatic heart failure. in such patients it is recommended that enalapril be administered together with a diuretic. left ventricular dysfunction. all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35%, irrespective of the presence or severity of obvious symptoms of heart failure.

Australien - Englisch - Department of Health (Therapeutic Goods Administration)

medis pharma pty ltd - enalapril maleate, quantity: 10 mg - tablet - excipient ingredients: lactose monohydrate; croscarmellose sodium; hypromellose; sodium stearylfumarate; maleic acid - hypertension ,enalapril is indicated in the treatment of all grades of essential hypertension and renovascular hypertension. ,congestive heart failure ,enalapril is indicated for the treatment of all degrees of symptomatic heart failure. in such patients, it is recommended that enalapril be administered together with a diuretic. ,left ventricular dysfunction ,all degrees of left ventricular dysfunction where the left ventricular ejection fraction is less than 35 percent, irrespective of the presence or severity of obvious symptoms of heart failure.